Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patent DocsAmgen Inc. v. F. Hoffman-La Roche Ltd. (Fed. Cir. 2009)
By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry
ADVERTISEMENTS
Something for Everyone, but the Injunction Stands By Kevin E. Noonan -- Amgen has several times successfully defended its erythropoietin (EPO) franchise, the company's first commercial success and in many ways the crown jewel of its (or anyone's) biologics drug pipeline. That string of successes continued today with a decision by the Federal Circuit against its latest challenger, Hoffman-La Roche. But the decision also put several of the patents protecting Amgen's EPO at risk, making this a mixed victory at best for the biotechnology company. The case involved the most recent challenge, Roche's Mircera® product, a pegylated derivative of human...Full post as published by Patent Docs on September 16, 2009 (boomark / email).
Lawsuits and Settlements
CellCept
Roche Issues Changes to Warnings and Adverse Events
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

Amgen whips Roche in Mircera case; injunction granted
Federal Circuit Addresses Effect of 271(e)(1) "Safe Harbor" in ITC Actions
Federal Circuit Revises: Amgen v. ITC
Roche Appeals Preliminary Anemia Drug Injunction









